Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model.
NIDDK/Navy Transplantation and Autoimmunity Branch, Naval Medical Research Center, Bethesda, Maryland, USA.
H
H
Xu
E
E
Elster
D
D
Batty
J
J
Berning
L
L
Burkly
R
R
Kampen
S
S
Swanson
D
D
Tadaki
D
D
Harlan
A
A
Kirk
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D023201:CD40 Ligand / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D006084:Graft Rejection / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008253:Macaca mulatta; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D023201:CD40 Ligand; D009173:Mycophenolic Acid